Tumors which have HER2 1+ or 2+ on IHC but ISH is negative make up approximately 50% of primary breast cancers. How familiar are you with HER2-low breast cancer? Learn more while testing your knowledge.
Associate Professor of Medicine , Section of Hematology/Oncology, Department of Medicine, Arizona Health Sciences Center, University of Arizona College of Medicine, Tucson, ArizonaAmerican Association for Cancer Research, American College of Physicians,
American Society of Clinical Oncology, American Society of Hematology, Hemostasis and Thrombosis Research Society, SWOGServe as a director, officer, partner, employee, advisor, consultant or trustee for: Bayer; Heron; Amgen; Athenex; Novartis; Eisai; Eli Lilly; Zentalis
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Does PREDICT Accurately Estimate Breast Cancer Survival?A study coordinated by Italian researchers investigated the prognostic performance of PREDICT in patients with early-stage HER2-positive breast cancer.
Baca lebih lajut »
Does PREDICT Accurately Estimate Breast Cancer Survival?A study coordinated by Italian researchers investigated the prognostic performance of PREDICT in patients with early-stage HER2-positive breast cancer.
Baca lebih lajut »
Fast Five Quiz: Non-Small Cell Lung Cancer and RET MutationPredictive biomarkers in NSCLC include gene fusions in tumors that have rearranged during transfection, or RET. What do you know about RET rearrangements in NSCLC?
Baca lebih lajut »
Fast Five Quiz: Gastric CancerGastric cancer is often diagnosed at an advanced stage and carries a poor prognosis. Knowing the risk factors can facilitate an early diagnosis and improve outcomes. Take the quiz for a quick review.
Baca lebih lajut »